For General Information, page-2407

I’m wary of treading into medical science comparisons, but some differences between ANP (ATL1102) and CAPR (CAP1002) imo on a cursory analysis.

1. CAP1002 is in phase three (pivotal) trial stage (HOPE-3) and has 4 years of data on their P2 trial (one year blinded with placebo, a gap year and then 2 years of OLE).

2. CAP1002 P2 and P3 trials include placebo group

3. CAP1002 - Intravenous doses every 3 months versus ATL1102 injections every week

4. CAP102 Results include cardio function as well as PUL 2.0. 6 of 9 boys had improved cardio function after two year OLE (open label extension) in P2 trial. ATL1102 is yet to prove it can affect heart function. I recall reading somewhere that this was a challenge with antisense oligonucleotides. Someone with more medical knowledge could correct me here.

5. Correct me if I’m wrong but CAP1002 trials cover both ambulant and non-ambulant boys

6. No toxicity issues and a US pathway well established. In ongoing meetings with FDA that they will soon publish minutes of the latest.

7. They create, own and develop their drugs. No licensing and/or payaway or limit to creating new drugs.

8. They have a distribution agreement in place for US and Japan markets with Nippon Shinyaku.

9. CAPR have 77 employees, 8 directors and 10 scientific advisors.


Apart from the above, ATL1102 could be a better treatment.